Back Pain News and Research

Latest Back Pain News and Research

More effective therapeutic exercises underutilized in treatment of chronic neck pain

Duke University and University of North Carolina (UNC) researchers report in the November issue of Arthritis Care & Research that narcotics and diagnostic testing are overused in treating chronic neck pain. Their findings indicate clinicians may overlook more effective treatments for neck pain, such as therapeutic exercise. According to reviews cited in the study, evidence to support the effectiveness of therapeutic exercise in treating chronic neck pain is good, yet only 53% of subjects were prescribed such exercise.

28 Oct 2010

TransPharma announces positive results of ViaDerm-hPTH Phase 1 trial for osteoporosis treatment

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today successful results of a 4 week Phase 1 trial of its new self-applied ViaDerm-hPTH(1-34) for the treatment of osteoporosis.

26 Oct 2010

$Cedars-Sinai to develop world's first biological treatment for compression fractures$

Cedars-Sinai to develop world's first biological treatment for compression fractures

A team of physicians and scientists from the Cedars-Sinai Regenerative Medicine Institute and Department of Surgery, led by Dan Gazit, DMD, PhD has been awarded a three-year $1.9 million grant from the California stem cell agency to fund research leading to clinical trials for what could become the first biological treatment for the most common type of bone fracture in osteoporosis patients.

25 Oct 2010

FDA approves REMS for NUVIGIL and PROVIGIL tablets

Cephalon, Inc. today announced that Risk Evaluation and Mitigation Strategies (REMS) for its medications NUVIGIL (armodafinil) Tablets [C-IV] and PROVIGIL (modafinil) Tablets [C-IV] have been approved by the U.S. Food and Drug Administration (FDA).

25 Oct 2010

Alexion announces results of eculizumab two open-label Phase 2 studies for aHUS treatment

Alexion Pharmaceuticals, Inc. today announced that its two open-label Phase 2 studies investigating eculizumab (Soliris) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) have met the primary and key secondary endpoints with high clinical and statistical significance, in interim analyses.

21 Oct 2010

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Abbott today announced financial results for the third quarter ended Sept. 30, 2010.

20 Oct 2010

$IOF urges health professionals and public to recognize signs of spinal fractures$

IOF urges health professionals and public to recognize signs of spinal fractures

A new report issued by the International Osteoporosis Foundation (IOF) for World Osteoporosis Day puts the spotlight on the severe impact of spinal fractures and calls on health professionals to recognize the signs of these fractures in their patients.

20 Oct 2010

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast (zoledronic acid) injection in postmenopausal women with osteoporosis.The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada.

19 Oct 2010

14 global studies on osteoporosis medications FORTEO and EVISTA to be presented at ASBMR 2010

Eli Lilly and Company today announced that a total of 14 U.S. and global studies involving its osteoporosis medications, FORTEO® [teriparatide (rDNA origin) injection] and EVISTA® (raloxifene HCl tablets), will be presented at the American Society for Bone and Mineral Research (ASBMR) 2010 Annual Meeting from October 15-19 in Toronto, ON, Canada.

18 Oct 2010

Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis

Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast (zoledronic acid) injection in postmenopausal women with osteoporosis. The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada.

18 Oct 2010

Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress

Acorda Therapeutics, Inc. today announced that a new analysis of AMPYRA (dalfampridine) Extended Release Tablets, 10 mg data examining walking improvement in treatment responders has been presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

15 Oct 2010

$Spinal fractures remain undiagnosed and untreated$

Spinal fractures remain undiagnosed and untreated

15 Oct 2010

FDA approves Gamunex-C for primary immunodeficiency treatment

Talecris Biotherapeutics announced today that the U.S. Food and Drug Administration (FDA) approved Gamunex-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency (PI).

15 Oct 2010

U.S. Bone and Joint Decade observes National Action Week

An annual global event, Bone and Joint National Action Week is held October 12-20 with activities focused on disorders including arthritis, back pain, osteoporosis, and the effects of childhood obesity on the musculoskeletal system. Events and projects organized worldwide are designed to raise awareness of prevention, disease management and treatments. In the United States, the U.S. Bone and Joint Decade represents the global initiative.

14 Oct 2010

Study compares minimally invasive and open surgeries for lower back pain

Rush University Medical Center is assessing whether minimally invasive surgery to relieve lower back pain differs from open surgery in terms of complication rate, recovery time, outcome and cost.

13 Oct 2010

$Photographic exhibition reveals devastating impact of spinal osteoporotic fractures$

Photographic exhibition reveals devastating impact of spinal osteoporotic fractures

At a press conference held in Brussels today, the International Osteoporosis Foundation (IOF), the Belgian Bone Club and the European Parliament Osteoporosis Interest Group called on health care professionals and health policy officials in Europe to take action to prevent spinal fractures. The call to action was made at the launch of a unique photographic essay, 'snap! the breaking spine', leading up to World Osteoporosis Day on October 20, 2010.

12 Oct 2010

Physical and psychological factors contribute to somatic symptoms: Report

Patients with cancer who experience pain or depression also have a high rate of physical symptoms, such as fatigue, dry mouth and nausea, according to a report in the October 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

12 Oct 2010

Proper treatment for scoliosis may help children to lead active lives

Scoliosis may sound like a frightening diagnosis, but proper treatment enables children with the condition to lead normal, active lives. Scoliosis refers to an abnormal curvature of the spine. Small curves are a normal part of spine anatomy and are not cause for concern, according to Dr. Daniel Green, a pediatric orthopedic surgeon at Hospital for Special Surgery in Manhattan. But when the curvature exceeds a certain range, children require medical attention.

12 Oct 2010

$Balloon kyphoplasty relieves painful spine fractures in patients with metastatic cancer$

Balloon kyphoplasty relieves painful spine fractures in patients with metastatic cancer

A surgical technique appears to offer quick and effective relief for debilitating spinal fractures often suffered by patients with metastatic cancer, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan.

11 Oct 2010

Abbott presents data from 4 briakinumab pivotal studies in psoriasis

In four separate pivotal clinical studies presented on Friday, a greater percentage of moderate to severe chronic plaque psoriasis patients treated with briakinumab, Abbott's investigational IL-12/23 inhibitor (ABT-874), achieved 75 percent or better skin clearance rates than those treated with etanercept (Enbrel®), methotrexate or placebo. Abbott presented data from all briakinumab pivotal studies in psoriasis at the European Association of Dermatology and Venereology scientific sessions.

11 Oct 2010

Back Pain News and Research

Latest Back Pain News and Research

More effective therapeutic exercises underutilized in treatment of chronic neck pain

TransPharma announces positive results of ViaDerm-hPTH Phase 1 trial for osteoporosis treatment

Cedars-Sinai to develop world's first biological treatment for compression fractures

FDA approves REMS for NUVIGIL and PROVIGIL tablets

Alexion announces results of eculizumab two open-label Phase 2 studies for aHUS treatment

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

IOF urges health professionals and public to recognize signs of spinal fractures

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

14 global studies on osteoporosis medications FORTEO and EVISTA to be presented at ASBMR 2010

Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis

Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress

Spinal fractures remain undiagnosed and untreated

FDA approves Gamunex-C for primary immunodeficiency treatment

U.S. Bone and Joint Decade observes National Action Week

Study compares minimally invasive and open surgeries for lower back pain

Photographic exhibition reveals devastating impact of spinal osteoporotic fractures

Physical and psychological factors contribute to somatic symptoms: Report

Proper treatment for scoliosis may help children to lead active lives

Balloon kyphoplasty relieves painful spine fractures in patients with metastatic cancer

Abbott presents data from 4 briakinumab pivotal studies in psoriasis

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Back Pain News and Research

Latest Back Pain News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in